EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The spectrum of bacterial infections in febrile neutropenic patients: effect on empiric antibiotic therapy



The spectrum of bacterial infections in febrile neutropenic patients: effect on empiric antibiotic therapy



Jpma. Journal of the Pakistan Medical Association 48(12): 364-367



The aim of this retrospective analysis was to look at the spectrum of bacterial isolates and their resistance patterns to the commonly used antibiotics in the setting of febrile neutropenia. A total of 127 bacteria were isolated from patients with acute leukemias, lymphoproliferative disorders, aplastic anaemia and various solid tumours. Fifty-four percent organisms were gram negative; while the rest were gram positive. E. coli, pseudomonas aeruginosa, staphylococcus aureus, enterococcus and streptococci were the commonly isolated organisms. Forty-eight percent organisms were isolated from blood, 16% from urine, 13% from wounds and superficial abscesses and 11% from respiratory tract. E. coli exhibited a great degree of resistance to the commonly used antibiotics, such as pipericillin (70%), ofloxacin (50%) and aztreonam (50%). Pseudomonas and klebsiella also showed varying degree of resistance against the antibiotics. Staphylococcus aureus and staphylococcus epidermidis were almost universally resistant to penicillin and showed a variable degree of resistance to other antibiotics too. Compared to the previous reports, the pattern of bacterial isolates and their resistance to antibiotics has changed over the past years. Aminoglycosides and third generation cephalosporins seem to be the choice of antibiotics for the upfront management of febrile neutropenic patients.

(PDF emailed within 1 workday: $29.90)

Accession: 047739837

Download citation: RISBibTeXText

PMID: 10531769



Related references

The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 11(5): 327-330, 1988

Prophylaxis and empiric therapy for streptococcal infections in febrile neutropenic patients. European Journal of Cancer 27(7): 818-819, 1991

The Use of Glycopeptides as Empiric Antibiotic Therapy in Febrile Neutropenic Patients: A Comparison Between Teicoplanin (TEI) and Vancomycin (VAN). Leukemia and Lymphoma 7(Sup2): 110-111, 1992

Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. American Journal of Medicine 78(6a): 62-72, 1985

Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: an overview. European Journal of Cancer & Clinical Oncology 25 Suppl 2: S37-S42, 1989

Use of different definitions of clinical response in trials of empiric anti-bacterial therapy of febrile episodes in neutropenic patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 593, 1998

Empiric therapy for bacterial infections in neutropenic patients. Cancer Treatment and Research 79: 101-112, 1995

Overview of empiric antibiotic therapy for the febrile neutropenic patient. Reviews of Infectious Diseases 7 Suppl 4: S734-S740, 1985

Empiric therapy for infections in the febrile, neutropenic, compromised host. Medical Clinics of North America 79(3): 559-580, 1995

Bloodstream infections in febrile neutropenic patients: bacterial spectrum and antimicrobial susceptibility pattern. Journal of Ayub Medical College, Abbottabad 16(1): 18-22, 2004

Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer. Antimicrobial Agents and ChemoTherapy 36(12): 2816-2820, 1992

Cost comparison of seven antibiotic combinations as empiric therapy in a simulated febrile neutropenic patient. American Journal of Hospital Pharmacy 42(11): 2484-2488, 1985

Piperacillin, tazobactam and gentamicin as empiric antibiotic treatment for febrile neutropenic patients with leukaemia. Onkologie 18(SUPPL 2): 196, 1995

A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients. British Journal of Haematology 76 Suppl 2: 41-44, 1990

A randomized prospective study of ceftazidime and ciproflaxacin with or without teicoplanin as an empiric antibiotic of regimen for febrile neutropenic patients. British Journal of Haematology 76(SUPPL 2): 41-44, 1990